Insulet Corporation PODD recently made its Omnipod 5 Automated Insulin Delivery (“AID”) System commercially available in Australia. Omnipod 5 is available with Dexcom G6 and G7 continuous glucose monitoring (“CGM”) sensor compatibility. 

The latest development represents a significant step forward in expanding access to its innovative, tubeless Omnipod 5 AID system for more people globally. 

PODD Stock’s Likely Trend Following the News

Following the announcement on March 18, PODD’s shares climbed 2% to $265.82 in Tuesday’s trading session. The company’s solid innovation efforts and ongoing expansion of the Omnipod 5 platform are solidifying its market leadership. We expect the market sentiment toward the PODD stock to remain positive surrounding this development.

Insulet has a market capitalization of $18.67 billion at present. Going by the Zacks Consensus Estimate, the company’s earnings are likely to increase 33% in 2025 on an 18.1% improvement in revenues. In the trailing four quarters, it delivered an earnings beat of 27.52%, on average.

About Insulet’s Omnipod 5

Omnipod 5 is the first and only FDA-cleared tubeless AID system indicated for individuals with type 1 and type 2 diabetes. Omnipod 5 system simplifies diabetes management and has shown an improvement in results by removing the need for multiple daily injections (“MDI”) therapy along with automatically adjusting insulin delivery every five minutes using its advanced SmartAdjust technology. 

Growing Presence of Insulet’s Omnipod 5

Omnipod 5 was first introduced in the United States in 2022 and has demonstrated strong clinical results with real-world evidence. In 2023, after the successful launch in the U.K. and Germany, Insulet introduced Omnipod 5 in France, one of its largest markets, and the Netherlands in June 2024. In January 2025, Omnipod 5 became available in five more countries, Italy, Denmark, Finland, Norway and Sweden, with both Abbott’s FreeStyle Libre 2 Plus and Dexcom G6 compatibility. Insulet recently expanded sensor integrations to include Dexcom G7 for Omnipod 5 users in the United Kingdom and the Netherlands.

Insulet’s Plans for Omnipod 5’s Expansion 

Insulet is anticipating to bring Omnipod 5 to more markets in the upcoming quarters of 2025. The company expects to launch Omnipod 5 in Belgium and Switzerland with Abbott’s FreeStyle Libre 2 Plus, and Dexcom G6 and G7 sensor integrations. In addition, Omnipod 5 will be launched in Canada with Dexcom G6 and G7 sensor compatibility. It will be soon available in five more markets including Israel, Saudi Arabia, the United Arab Emirates, Qatar and Kuwait. 

Image Source: Zacks Investment Research

Industry Prospects Favor PODD

Per a report by Towards Healthcare, the global insulin delivery system market size is calculated at $17.77 in 2024 and is projected to reach $38.09 billion by 2034. The market is expanding at a compound annual rate of 7.92% between 2024 and 2034. The increasing number of diabetic patients and technological advancements like automation, AI and machine learning are going to support the growth of the market.

Another Development by PODD

Yesterday, Insulet unveiled favorable RADIANT trial clinical data for its Omnipod 5 at the 18th International Conference on Advanced Technologies and Treatments for Diabetes. The RADIANT trial results demonstrate Omnipod 5 to be clinically efficient for people living with type 1 diabetes. 

PODD Stock’s Price Performance

In the past year, Insulet’s shares have gained 61.5% compared with the industry’s growth of 10.6%.

PODD’s Zacks Rank & Other Key Picks

Insulet currently carries a Zacks Rank #2 (Buy).

Some other top-ranked stocks in the broader medical space are Masimo MASI, Boston Scientific BSX and Cardinal Health CAH. At present, Masimo sports a Zacks Rank #1 (Strong Buy), whereas Boston Scientific and Cardinal Health carry a Zacks Rank #2. You can see the complete list of today’s Zacks #1 Rank stocks here.

Masimo shares have rallied 26.5% in the past year. Estimates for MASI’s 2024 earnings per share (EPS) have increased 1.2% to $4.10 in the past 30 days. MASI’s earnings beat estimates in each of the trailing four quarters, the average surprise being 17.1%. 

Estimates for Boston Scientific’s 2025 EPS have jumped 2.9% to $2.85 in the past 30 days. Shares of the company have surged 47.1% in the past year compared with the industry’s growth of 9.5%. BSX’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 8.25%. 

Estimates for Cardinal Health’s fiscal 2025 EPS have increased 1.5% to $7.94 in the past 30 days. Shares of the company have jumped 17.5% in the past year against the industry’s 3.2% decline. CAH’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 9.6%. 

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Boston Scientific Corporation (BSX) : Free Stock Analysis Report

Cardinal Health, Inc. (CAH) : Free Stock Analysis Report

Masimo Corporation (MASI) : Free Stock Analysis Report

Insulet Corporation (PODD) : Free Stock Analysis Report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research